Genedata in Screening Analysis Collaboration with Chugai in Japan

During the past twelve months Genedata Screener has provided computational support throughout a complete screening cycle at Chugai. Beginning with assay optimization and followed by primary and validation screening phases, Screener has enhanced Chugai’s search for active compounds with more robust measures for biological effects within the screening cascade.

Genedata’s computational scientists in Japan, based in Tokyo, have integrated Genedata Screener with research infrastructure at Chugai. It has been connected to Chugai’s screening platforms and result databases, providing data quality assurance and automating the analysis process from the plate readers all the way to the corporate databases.

Chugai’s screening experts use the AssayAnalyzer module to gain an overview of data quality for entire screening campaigns. Genedata’s Condoseo module is used to estimate the potency of compounds screened at multiple concentrations in the validation screening phase.

Actions speak louder than words

Genedata’s collaboration with Chugai began with a case study performed on data generated at Chugai’s research facilities in Kamkura, near Tokyo. Genedata analyzed a complete data set composed of primary and validation screening data, and presented the results to Chugai’s scientists.

The case study demonstrated the speed and efficiency of Genedata’s computational approach to screening analysis. “Data visualization and data quality assurance were key drivers behind choosing Genedata’s solution”, explained Hiroki Takaya, Group Manager, Pharmaceutical Technology Department, Chugai Pharmaceutical Co., Ltd.

This is Genedata Screener’s first collaboration in Japan. “We are strengthening our customer base internationally and our success with Chugai validates our approach to achieving close collaboration with customers on a global scale”, said Dr. Stephan Heyse, Head of Genedata Screener, Genedata AG.